WallStSmart

Medtronic PLC (MDT)vsInsulet Corporation (PODD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 1210% more annual revenue ($35.48B vs $2.71B). MDT leads profitability with a 13.0% profit margin vs 9.1%. MDT appears more attractively valued with a PEG of 1.50. PODD earns a higher WallStSmart Score of 57/100 (C).

MDT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 7.3Quality: 5.0

PODD

Buy

57

out of 100

Grade: C

Growth: 8.0Profit: 7.5Value: 4.7Quality: 6.8
Piotroski: 5/9Altman Z: 2.31
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MDTSignificantly Overvalued (-255.7%)

Margin of Safety

-255.7%

Fair Value

$24.34

Current Price

$87.89

$63.55 premium

UndervaluedFair: $24.34Overvalued
PODDSignificantly Overvalued (-452.8%)

Margin of Safety

-452.8%

Fair Value

$45.38

Current Price

$216.00

$170.62 premium

UndervaluedFair: $45.38Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$110.62B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.30B8/10

Generating 2.3B in free cash flow

PODD1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
31.2%10/10

Revenue surging 31.2% year-over-year

Areas to Watch

MDT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

PODD4 concerns · Avg: 3.5/10
PEG RatioValuation
1.594/10

Expensive relative to growth rate

Price/BookValuation
10.0x4/10

Trading at 10.0x book value

EPS GrowthGrowth
3.9%4/10

3.9% earnings growth

P/E RatioValuation
62.1x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.

Bull Case : PODD

The strongest argument for PODD centers on Revenue Growth. Revenue growth of 31.2% demonstrates continued momentum.

Bear Case : MDT

The primary concerns for MDT are EPS Growth.

Bear Case : PODD

The primary concerns for PODD are PEG Ratio, Price/Book, EPS Growth. A P/E of 62.1x leaves little room for execution misses.

Key Dynamics to Monitor

MDT profiles as a value stock while PODD is a hypergrowth play — different risk/reward profiles.

PODD carries more volatility with a beta of 1.44 — expect wider price swings.

PODD is growing revenue faster at 31.2% — sustainability is the question.

MDT generates stronger free cash flow (2.3B), providing more financial flexibility.

Bottom Line

PODD scores higher overall (57/100 vs 56/100) and 31.2% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Insulet Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts.

Want to dig deeper into these stocks?